OncoStem develops prognostic tests for cancer detection. Its flagship product CanAssist-Breast uses a proprietary AI-based statistical model to identify patient risk of breast cancer recurrence, providing additional tumor information for customized cancer treatment. Founded in 2011 in Bengaluru, India, the company has raised $9.0M in Series A funding from investors including Artiman and Peak XV Partners. Developer of prognostic tests for the detection of cancer. The company's flagship product is CanAssist-Breast, which uses a proprietary Artificial Intelligence-based statistical model to identify the patient's risk of breast cancer recurrence. Also, it provides additional information about the tumor, based on which the cancer treatment can be customized. Founded in 2011, headquartered in Bengaluru, India.
OncoStem
Series AOncoStem develops prognostic tests for cancer detection. Its flagship product CanAssist-Breast uses a proprietary AI-based statistical model to identify patient risk of breast cancer recurrence, providing additional tumor information for customized cancer treatment. Founded in 2011 in Bengaluru, India, the company has raised $9.0M in Series A funding from investors including Artiman and Peak XV Partners. Developer…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Women's Cancer > Breast Cancer > Prognosis,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine
Team background
College Wise > Indian Institute of Science
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.